Tipranavir - PharmaKB

Aptivus(tipranavir)

Aptivus (tipranavir) is a small molecule pharmaceutical. Tipranavir was first approved as Aptivus on 2005-06-22. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
urogenital diseases	D000091642
immune system diseases	D007154

Trade Name

FDA

EMA

Aptivus (discontinued: Aptivus)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Tipranavir

Tradename	Company	Number	Date	Products
APTIVUS	Boehringer Ingelheim	N-021814 RX	2005-06-22	1 products, RLD, RS

Show 1 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
aptivus	New Drug Application	2024-05-17

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
acquired immunodeficiency syndrome	EFO_0000765	D000163	B20

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

J: Antiinfectives for systemic use

— J05: Antivirals for systemic use

— J05A: Direct acting antivirals

— J05AE: Protease inhibitors, direct acting antivirals

— J05AE09: Tipranavir

HCPCS

No data

Clinical

Clinical Trials

77 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hiv infections	D015658	EFO_0000764	B20	8	15	13	4	10	44
Hiv	D006678	—	—	—	—	1	1	2	4
Cardiovascular diseases	D002318	HP_0001626	—	—	—	—	1	—	1
Lipodystrophy	D008060	HP_0009125	E88.1	—	—	—	1	—	1
Hiv-associated lipodystrophy syndrome	D039682	EFO_1001348	—	—	—	—	1	—	1

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Infections	D007239	EFO_0000544	—	1	—	1	—	4	6
Communicable diseases	D003141	—	—	1	—	1	—	4	6
Acquired immunodeficiency syndrome	D000163	EFO_0000765	B20	1	1	1	—	2	4
Immunologic deficiency syndromes	D007153	HP_0002721	D84.9	—	1	1	—	—	1

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Sarcoma	D012509	—	—	—	1	—	—	—	1
Kaposi sarcoma	D012514	—	C46	—	1	—	—	—	1

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	27	—	—	—	—	27
Liver failure	D017093	HP_0001399	K72.9	2	—	—	—	—	2
Hepatic insufficiency	D048550	—	—	2	—	—	—	—	2
Alcoholic liver cirrhosis	D008104	EFO_1000802	K70.3	1	—	—	—	—	1
Hepatitis	D006505	HP_0012115	K75.9	1	—	—	—	—	1

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Tipranavir
INN	tipranavir
Description	Tipranavir is a pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor. It has a role as a HIV protease inhibitor and an antiviral drug.
Classification	Small molecule
Drug class	antivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1